IMPACT Medicom

Precision Medicine in Oncology: Ep.8. Importance of BRCA testing for Advanced Epithelial Ovarian Cancer

December 07, 2021 IMPACT Medicom
IMPACT Medicom
Precision Medicine in Oncology: Ep.8. Importance of BRCA testing for Advanced Epithelial Ovarian Cancer
Show Notes

Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country.

Our Guests:
Dr. Janice Kwon, Gynecologic Oncologist at Vancouver Coastal Health and Vice Head and Professor in the Department of Obstetrics and Gynecology at the University of British Columbia. Dr. Kwon serves as Chair of both the Priority and Evaluations Committee at BC Cancer and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducing
interventions.

Dr. Alon Altman, Gynecologic Oncologist and Professor at the University of Manitoba, and the Winnipeg Health Sciences Centre/Cancercare Manitoba.  Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (the GOC). He is actively involved in multiple other university, national and international committees including serving as program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, and Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee.

This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com